Psyence Biomedical Ltd (PBM) Stock Price, Quote & News

Company Profile

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Industry: Biotechnology

Sector: Healthcare

Phone: 416-477-1708

Website: psyencebiomed.com

Address:

121 Richmond Street West, Penthouse Suite 1300, Toronto, Canada

RuddyRolls Aug. 24 at 4:51 PM

$PBM I bo GAIN Opioid crisis is well out of hand. Kennedy intent on attending to this - has personally lost more than one close family member to it. PTSD/ suicide rate for veterans is terrible. Something Trump will feel strongly about. I think Ibogaine trials will soon get the same set of fast-track tickets we've seen the FDA award to the classic psychedelic companies in the space. Steady steam of news from now on.

0 · Reply

1978280Z Aug. 23 at 7:32 PM

$PBM muh squeezy

0 · Reply

blackcat643 Aug. 22 at 11:13 AM

$PBM this babe is flying hard next week,just no delay or something from fda all we need keep it up 4.we shall see big 10/14 again

0 · Reply

RuddyRolls Aug. 22 at 10:00 AM

$PBM "Phoenix NPR affiliate KJZZ reports that Arizona’s health department has awarded a $5 million grant to the Barrow Neurological Institute and Arizona State University to study ibogaine in the treatment of PTSD and brain injury. The money came from a 2023 appropriations bill that earmarked the money for ibogaine research." https://www.kjzz.org/science/2026-08-18/arizona-awards-5-million-grant-to-barrow-neurological-institute-to-study-ibogaine-for-brain-injuries?utm_source=substack&utm_medium=email

0 · Reply

RuddyRolls Aug. 22 at 9:45 AM

$PBM "On Tuesday, President Donald Trump published a note on his social media site Truth Social announcing that the University of Miami gave Health & Human Services Secretary Robert F. Kennedy “its original 1994 ibogaine Investigational New Drug application” or IND. In order to study experimental drugs like psychedelics, researchers need to apply for an IND from the U.S. Food and Drug Administration showing preclinical data with non-human animals suggesting the drug is safe to test in humans, and protocols for future studies. In 1993, Deborah Mash, a professor at University of Miami and now the CEO of noribogaine company DemeRx, received IND approval from the FDA for her early studies of ibogaine. Ibogaine is a psychoactive compound that comes from the Tabernanthe iboga shrub, which grows in central and west Africa." https://themicrodose.substack.com/p/what-is-an-embedded-brain-johnson

1 · Reply

Ge8888 Aug. 21 at 5:17 PM

$PBM lets move to $ 5-10

0 · Reply

RuddyRolls Aug. 21 at 9:02 AM

$PBM I asked Grok and GPT the below. Sharing for those considering the competitive advantage of their at-source supply chain and opportunity parameters/ realistic timelines to meaningful revenue for ibogaine supply. "I have some $PBM shares. Question - how many other competitors are there globally that could supply medical research grade Ibogaine? And therefore what odds of them getting meaningful supply contracts in the space soon and over coming years - and at what value potentially?" https://chatgpt.com/s/t_6a88133113488191bda195abb1bec920 https://grok.com/share/c2hhcmQtMw_c7bb1262-0661-45e1-a8ea-ce11c7a4bbf6

0 · Reply

Ge8888 Aug. 20 at 4:37 PM

$PBM v

0 · Reply

RuddyRolls Aug. 19 at 11:51 PM

$PBM few sellers to clear from the last run I suspect. Fair enough, clear a few baggies. The fundamentals for a contract announcement or similar news are as good as it gets right now. Hopefully this time we can be a bit more incremental and hold our gains around $10-$20 with something solid landing. Anyway she is simmering. Sit pretty while our lads tour America seeking Actual Supply Contracts or at least a few MOUs. (Lion's Mane) Coffee is for closers Jody!

0 · Reply

Ge8888 Aug. 19 at 8:52 PM

$PBM

0 · Reply

Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development

Jun 16, 2026, 10:00 AM EDT - 2 months ago

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

2026-05-15T14:51:49.000Z - 3 months ago

Psyence Biomedical announces U.S. engagement initiative focused on ibogaine

May 15, 2026, 9:15 AM EDT - 3 months ago

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Apr 23, 2026, 7:00 AM EDT - 4 months ago

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

2026-04-20T12:19:33.000Z - 4 months ago

Psyence Biomedical provides update on position in global ibogaine market

Apr 20, 2026, 7:42 AM EDT - 4 months ago

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

2026-04-18T00:33:00.000Z - 4 months ago

Why Is Psyence Biomedical Stock (PBM) Up Today?

2026-04-17T19:16:22.000Z - 4 months ago

Psyence Biomedical Ltd trading resumes

2026-04-17T19:12:01.000Z - 4 months ago

Psyence Biomedical Ltd trading halted, volatility trading pause

2026-04-17T13:26:00.000Z - 4 months ago

Psyence acknowledges reports on U.S. action to advance Ibogaine research

Apr 17, 2026, 9:15 AM EDT - 4 months ago

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Apr 8, 2026, 9:15 AM EDT - 4 months ago

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Mar 11, 2026, 9:15 AM EDT - 5 months ago

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

2026-03-03T14:22:48.000Z - 6 months ago

Psyence Biomedical announces export of psilocybin to Australia

Mar 3, 2026, 9:15 AM EST - 6 months ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Feb 20, 2026, 5:20 PM EST - 6 months ago

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

2026-02-17T14:27:42.000Z - 6 months ago

Psyence Biomedical announces results of annual, special meeting

Feb 17, 2026, 9:15 AM EST - 6 months ago

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Feb 13, 2026, 6:30 PM EST - 6 months ago

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

2026-02-11T14:20:57.000Z - 6 months ago

Psyence Biomedical announces settlement of shareholder litigation

Feb 11, 2026, 9:15 AM EST - 6 months ago

Psyence BioMed Announces Settlement of Shareholder Litigation

Jan 28, 2026, 6:30 PM EST - 7 months ago

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Jan 22, 2026, 1:42 PM EST - 7 months ago

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Jan 20, 2026, 7:19 AM EST - 7 months ago

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Jan 12, 2026, 8:30 AM EST - 8 months ago

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Jan 5, 2026, 9:15 AM EST - 8 months ago

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Dec 19, 2025, 7:00 AM EST - 8 months ago

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Dec 9, 2025, 7:00 AM EST - 9 months ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Nov 25, 2025, 7:00 AM EST - 9 months ago

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Nov 20, 2025, 7:00 AM EST - 9 months ago

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Nov 12, 2025, 7:00 AM EST - 10 months ago

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 6, 2025, 7:00 AM EST - 10 months ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 3, 2025, 7:00 AM EST - 10 months ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Aug 28, 2025, 8:00 AM EDT - 1 year ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jun 25, 2025, 5:00 PM EDT - 1 year ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 1 year ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 8:30 AM EDT - 1 year ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

May 27, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 1, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Apr 17, 2025, 7:17 PM EDT - 1 year ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 9:39 AM EDT - 1 year ago

Psyence Group Announces Share Consolidation

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 10, 2025, 11:18 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 1 year ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Dec 27, 2024, 4:05 PM EST - 1 year ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 23, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 17, 2024, 8:37 AM EST - 1 year ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 7:30 AM EST - 1 year ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

RuddyRolls Aug. 24 at 4:51 PM

0 · Reply

1978280Z Aug. 23 at 7:32 PM

$PBM muh squeezy

0 · Reply

blackcat643 Aug. 22 at 11:13 AM

$PBM this babe is flying hard next week,just no delay or something from fda all we need keep it up 4.we shall see big 10/14 again

0 · Reply

RuddyRolls Aug. 22 at 10:00 AM

0 · Reply

RuddyRolls Aug. 22 at 9:45 AM

1 · Reply

Ge8888 Aug. 21 at 5:17 PM

$PBM lets move to $ 5-10

0 · Reply

RuddyRolls Aug. 21 at 9:02 AM

0 · Reply

Ge8888 Aug. 20 at 4:37 PM

$PBM v

0 · Reply

RuddyRolls Aug. 19 at 11:51 PM

0 · Reply

Ge8888 Aug. 19 at 8:52 PM

$PBM

0 · Reply

Alarusso68 Aug. 19 at 7:25 PM

$PBM and down we go!

0 · Reply

VolcanicTrades Aug. 19 at 2:53 PM

$PBM this is probably going back to double digits with government

1 · Reply

prismmarketview Aug. 19 at 1:21 PM

President Trump today revealed that the University of Miami handed over its original 1994 ibogaine IND application to the federal government; a step he says could accelerate the compound's path toward becoming an approved medical treatment in the U.S. Psyence BioMed ( $PBM ) welcomed the news, with CEO Jody Aufrichtig calling it "what Psyence BioMed was built for." The company already holds a stake in PsyLabs, a GMP-compliant manufacturing operation producing pharmaceutical-grade ibogaine hydrochloride, positioning it to support U.S. clinical development as HHS, the VA, and FDA deepen their engagement with the compound. Aufrichtig and CFO Warwick Corden-Lloyd are in Texas this week meeting with stakeholders shaping the emerging U.S. ibogaine ecosystem. https://prismmarketview.com/companies/psyence-biomedical-ltd-common-shares/#news

0 · Reply

momoneyinfla Aug. 18 at 11:57 PM

$PBM nothing? 😂

1 · Reply

focafoca99 Aug. 18 at 11:32 PM

$PBM hails U.S. administration's push to accelerate ibogaine development, citing new presidential support.

0 · Reply

RuddyRolls Aug. 18 at 11:14 PM

$PBM Lead story in The Microdose this week (brought to you by the U.C. Berkeley Center for the Science of Psychedelics.) "Veterans Affairs continues to drive federal psychedelic push I got to ask U.S. Department of Veterans Affairs Secretary Doug Collins a few questions during his visit to Seattle’s VA Medical Center on August 7. He re-iterated that ibogaine would be the agency’s next emphasis. Ibogaine is a psychoactive compound that comes from the Tabernanthe iboga shrub, which grows in equatorial Central and West Africa. Researchers have also synthesized ibogaine in a laboratory. Collins acknowledged that federal sourcing for ibogaine is still a work in progress. “Ibogaine is not available in the United States until we get the protocols,” Collins said. “We’re actually hopeful to get some cooperation. You know, within the realms of discussion with those that are across the border.”" https://themicrodose.substack.com/p/veterans-affairs-continues-to-drive

0 · Reply

Jbjb90 Aug. 18 at 10:51 PM

$PBM https://www.stocktitan.net/news/PBM/psyence-bio-med-welcomes-u-s-administration-s-latest-action-to-k14a643ipdr1.html

0 · Reply

RuddyRolls Aug. 18 at 10:28 PM

$PBM Diamond. "PsyLabs is a core component of Psyence BioMed’s ibogaine strategy, providing manufacturing infrastructure and pharmaceutical expertise as the United States moves toward establishing regulated pathways for ibogaine research and development. “The conversation around ibogaine has changed dramatically,” Aufrichtig continued. “This is no longer a discussion taking place at the margins of medicine. The White House, HHS, the VA, FDA, researchers and states are increasingly asking how ibogaine can be studied safely, responsibly and at the standards expected of a pharmaceutical medicine. Those are exactly the questions we have been preparing to help answer.”"

0 · Reply

RuddyRolls Aug. 18 at 10:26 PM

$PBM Platinum. "Aufrichtig {PBM CEO} and Psyence BioMed Chief Financial Officer Warwick Corden-Lloyd are currently in Texas meeting with stakeholders and other leaders in the emerging U.S. ibogaine ecosystem to discuss recent progress, the evolving regulatory and policy environment, and opportunities to advance the responsible clinical development of ibogaine in the United States. "The timing of the President’s announcement is particularly meaningful as Warwick and I are here in Texas engaging directly with stakeholders who are working to turn this growing momentum into tangible progress,” Aufrichtig added. “There is a real sense of urgency around this work, particularly for veterans, and Psyence BioMed intends to be an active participant in determining what comes next.”"

0 · Reply

RuddyRolls Aug. 18 at 10:24 PM

$PBM Gold. "The President also highlighted progress since his April Executive Order, including HHS research funding, HHS-VA collaboration, FDA guidance and efforts to expand Right to Try access for veterans. President Trump concluded his statement with a call for additional companies and institutions to participate in the effort. “This is what Psyence BioMed was built for,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “The President has made clear that the United States wants serious companies and institutions to step forward and help advance ibogaine. We are ready to answer that call.”"

0 · Reply

Market Cap	9.93M
Revenue (ttm)	0.00
Net Income (ttm)	-6.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	36,949
Avg Vol	89,568
Day's Range	N/A - N/A
Shares Out	2.29M
Stochastic %K	62%
Beta	1.66
Analysts	Strong Buy
Price Target	N/A